Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $5,275.0M | $6,532.0M | $6,388.0M | $6,077.0M | $7,453.0M | $9,458.0M | $11.8B | $11.9B | $10.9B | $9,399.0M | $10.2B | $8,046.0M | $8,596.0M | $9,875.0M | $10.9B | $11.4B | $11.1B | $12.1B | $11.6B | $11.7B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novartis AG's last 12-month Free Cash Flow is $12.5B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novartis AG's Free Cash Flow growth was (5.4%). The average annual Free Cash Flow growth rates for Novartis AG have been 6.7% over the past three years, 2.0% over the past five years.
Over the last year, Novartis AG's Free Cash Flow growth was (5.4%), which is lower than industry growth of (0.2%). It indicates that Novartis AG's Free Cash Flow growth is Bad.